Adrestia Therapeutics: Adrestia appoints Head of Chemistry and initiates multi-target partnership with Proteros to discover first-in-class drugs for intractable genetic diseases
Drug discovery leader Dr James Osborne brings strong track record of delivering drug candidates for oncology and CNS disorders Proteros selected for its cutting-edge structure-based drug
United Kingdom Switzerland General Nordrhein Westfalen Tom Donovan Tom Heightman Kostenloser Wertpapierhandel
Source: finanznachrichten.de